Albert David
669.90
-4.20(-0.62%)
Market Cap₹382.32 Cr
PE Ratio40.11
IndustryHealthcare
Company Performance:
1D-0.62%
1M-8.97%
6M-16.54%
1Y-15.93%
5Y+68.93%
View Company Insightsright
More news about Albert David
04Aug 25
Albert David Limited Reports Mixed Q1 FY2026 Results with Decline in Revenue and Profit
Albert David, a pharmaceutical company, released Q1 FY2026 results showing a 21% year-on-year revenue decline to Rs. 7,056.64 lakhs. Net profit fell 58% to Rs. 793.76 lakhs. EPS decreased to Rs. 13.91 from Rs. 33.02 in Q1 FY2025. The company's equity share capital remained unchanged at Rs. 570.72 lakhs. The results were approved by the board on August 2, 2025, after a limited review by statutory auditors.
 no imag found
02Aug 25
Albert David Limited Appoints Pharma Veteran as New Independent Director, Approves Q1 Results
Albert David Limited's board approved Q1 financial results for the quarter ended June 30, 2025. The company appointed Dr. Rajiv Anant Desai as an Additional Non-Executive Independent Director, effective August 2, 2025, subject to shareholder approval via postal ballot. Dr. Desai, 63, brings 38 years of pharmaceutical industry experience, including roles at Lupin Limited and Indian Pharmaceutical Alliance. His appointment is for a five-year term.
 no imag found
02Aug 25
Albert David Reports 59% Decline in Q1 Net Profit, Appoints New Independent Director
Albert David Limited's Q1 net profit declined by 59.30% to ₹77.50 million from ₹190.40 million year-over-year. The Board approved Q1 financial results and appointed Dr. Rajiv Anant Desai as Additional Non-Executive Independent Director for five years, effective August 2, subject to shareholder approval. Dr. Desai brings 38 years of pharmaceutical industry experience, including roles at Indian Pharmaceutical Alliance and Lupin Limited.
 no imag found
13May 25
Albert David Ltd Reports Q4 FY23 Results: EBITDA Loss Widens, Revenue Declines; Recommends Dividend
Albert David Ltd's Q4 FY23 results show a 15.94% YoY revenue decline to ₹749.00 crore. EBITDA swung to a loss of ₹48.00 crore from a profit of ₹96.00 crore in Q4 FY22. Net loss improved by 20.16% YoY to ₹103.00 crore. The company recommended a dividend of ₹5 per equity share despite financial challenges.
 no imag found
Albert David
669.90
-4.20
(-0.62%)
1 Year Returns:-15.93%
Industry Peers
Sun Pharmaceutical
1,794.40
(+0.63%)
Divis Laboratories
6,086.50
(+0.26%)
Torrent Pharmaceuticals
4,305.50
(+0.91%)
Dr Reddys Laboratories
1,283.80
(+0.54%)
Lupin
2,298.20
(+0.34%)
Cipla
1,281.90
(-1.39%)
Zydus Life Science
889.80
(+0.33%)
Mankind Pharma
2,068.20
(-1.27%)
Aurobindo Pharma
1,286.00
(+0.50%)
Alkem Laboratories
5,333.50
(+0.20%)